search
Back to results

Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic

Primary Purpose

Covid19, Intellectual Disability, Developmental Disability

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
General Communication Message
Focused/Targeted Message
Best Message Alone
Best Message + Augmented Message or Implementation Strategy
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Covid19

Eligibility Criteria

5 Years - 90 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Students enrolled in the St. Louis Special School District or the Kennedy Krieger Institutes/Sheppard Pratt Schools in Maryland.
  • Teachers/Staff working at the St. Louis Special Schools or the Kennedy Krieger Institutes/Sheppard Pratt Schools in Maryland dedicated to teaching children with IDD.

or

  • Parents/ of students, teachers and/or staff employed by the St. Louis Special School District or Kennedy Krieger Institute/Sheppard Pratt schools in Maryland or
  • Families, teachers, and staff of the 67 University Centers for Excellence in Developmental Disabilities (UCEDD) which is sponsored by the Association of University Centers for Disability (AUCD).

Exclusion Criteria:

  • Members of the research team will not be eligible to participate in the focus groups.

Sites / Locations

  • Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
  • University of Missouri
  • Special School District

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

General Message

Focus/Targeted Message

Best Message Alone

Best Message + Augmented Message or Implementation Strategy

Arm Description

In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that generally describes COVID-19 and the importance of testing.

In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the FG input.

In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy alone to begin at 7 months after testing starts.

In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.

Outcomes

Primary Outcome Measures

Adoption of weekly testing by each participant
Ratio of the total number test per the number of weeks of analysis (eg. Phase 1 - 20 weeks)

Secondary Outcome Measures

Acceptability of Messaging/Implementation Strategy
The acceptability of each strategy will be assessed with a validated survey of the families and staff prior to the intervention and at the conclusion of the intervention being utilized.
Feasibility of Messaging/Implementation Strategy
The feasibility of each strategy will be assessed with a validated survey of the families and staff prior to the intervention and at the conclusion of the intervention being utilized.
Appropriateness of Messaging/Implementation Strategy
The appropriate of each strategy will be assessed with a validated survey of the families and staff prior to the intervention and at the conclusion of the intervention being utilized.
Number of missed school days by students or work days by staff
The total number of days missed by students and staff at the special schools during the 52 weeks of the study will be obtained.
Students and staff positive SARS-CoV-2 virus
The percentage of students and staff positive for SARS-CoV-2 virus will be determined
School-based SARS-CoV-2 transmission events
Number of possible SARS-CoV-2 transmission events occurring between students and staff within the school setting.

Full Information

First Posted
September 24, 2020
Last Updated
July 24, 2023
Sponsor
Washington University School of Medicine
Collaborators
University of Missouri, Kansas City, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT04565509
Brief Title
Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic
Official Title
Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 20, 2020 (Actual)
Primary Completion Date
May 31, 2023 (Actual)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Washington University School of Medicine
Collaborators
University of Missouri, Kansas City, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary goal of this project is to identify the best messaging and implementation strategies to maximize SARS-CoV-2 testing for children with intellectual and developmental disabilities (IDD) and their teachers to help ensure a safe school environment. Additionally, we will understand nationally the perceptions of COVID-19 and identify facilitators and barriers to help with the adoption of testing in other parts of the US and the necessary strategies to address other mitigation strategies including vaccination.
Detailed Description
This research study will occur at six schools dedicated to children with IDD that are a part of the Special School Districts in St. Louis, MO. Additionally, surveys, focus groups, and fuzzy cognitive mapping sessions will be conducted at these six schools and at schools within the Kennedy Krieger School Programs in Baltimore, MD. Finally, a national survey will be administered to families, teachers, and staff of the 67 University Centers for Excellence in Developmental Disabilities (UCEDD) which is sponsored by the Association of University Centers for Disability (AUCD). The first aim will involve focus groups of parents/guardians, teachers, and school staff to identify the barriers and facilitators to frequent SARS-CoV-2 testing, impressions of COVID-19, and best messages and implementation strategies to promote increase testing and vaccination. A formal process for developing two types of messages (general versus focused) will be performed using focus group data and involving key stakeholders to test the messages. A cluster randomized adaptive clinical trial will then occur at the six special school district schools. In phase 1, the schools will be randomized initially to either the general or focused message to promote the adoption of weekly SARS-CoV-2 testing by the students and teachers. After 5 months, data analysis will be conducted to determine which strategy led to the highest percentage of testing. Phase 2 will begin at 7 months after the schools are randomized to either the best message determined from phase 1 or best message plus an augmented implementation strategy. Beginning in April 2021 the first aim was expanded to include weekly testing and message development at the Kennedy Krieger Institutes and Sheppard Pratt Schools in Baltimore, MD. In phase 1, these schools will be randomized initially to either the general or focused message to promote the adoption of weekly SARS-CoV-2 testing by the students and teachers. After 5 months, data analysis will be conducted to determine which strategy led to the highest percentage of testing. Phase 2 will begin at 7 months after these schools are randomized to either the best message determined from phase 1 or best message plus an augmented implementation strategy. The second aim will assess the national perspectives among parents of children with IDD and school staff regarding the impact of COVID-19 and importance of SARS-CoV-2 testing. Fuzzy cognitive mapping (FCM) and the administration of local and national surveys will be used to accomplish this aim. FCM will involve in-person sessions with parents from the schools in aim 1 and Kennedy Krieger Institute/Sheppard Pratt schools in Baltimore, MD for children with IDD. These sessions will help identify the facilitators and barriers SARS-CoV-2 testing and other mitigation strategies including COVID-19 vaccine. Since no accepted measures have been developed for understanding parent and school staff concerns for children with IDD around COVID-19, local (St. Louis and Baltimore) and national surveys will be conducted. Custom surveys will be deployed across two stakeholder groups: parent/guardians and school staff. We will administer the survey at baseline and during the trial across school settings (St. Louis and Baltimore). A national survey will also be administered across the UCEDDs. Psychometric analysis will be performed to help identify the questions for a national survey at the end of the study period. In addition to the custom surveys, NIH recommended parent-report surveys from the PhenX Toolkit will be used. The surveys to be used include the Psychological Stress Associated with the COVID-19 Crisis Scale and COVID-19 impact questionnaires.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid19, Intellectual Disability, Developmental Disability, Child Development Disorder

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
A cluster randomized adaptive trial will be conducted. The first phase will randomize the 6 Special School District schools to either a general message or focus/targeted message. Data analysis will occur and then the schools will be randomized to the best message strategy from phase 1 alone or best message plus and augmented message or implementation strategy. The same process will take place independently at the Kennedy Krieger Institutes/Sheppard Pratt Schools.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3000 (Actual)

8. Arms, Groups, and Interventions

Arm Title
General Message
Arm Type
Active Comparator
Arm Description
In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that generally describes COVID-19 and the importance of testing.
Arm Title
Focus/Targeted Message
Arm Type
Active Comparator
Arm Description
In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the FG input.
Arm Title
Best Message Alone
Arm Type
Active Comparator
Arm Description
In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy alone to begin at 7 months after testing starts.
Arm Title
Best Message + Augmented Message or Implementation Strategy
Arm Type
Active Comparator
Arm Description
In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
Intervention Type
Behavioral
Intervention Name(s)
General Communication Message
Intervention Description
A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.
Intervention Type
Behavioral
Intervention Name(s)
Focused/Targeted Message
Intervention Description
A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.
Intervention Type
Behavioral
Intervention Name(s)
Best Message Alone
Intervention Description
The best message will be either the general or focused/targeted message described above.
Intervention Type
Behavioral
Intervention Name(s)
Best Message + Augmented Message or Implementation Strategy
Intervention Description
The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
Primary Outcome Measure Information:
Title
Adoption of weekly testing by each participant
Description
Ratio of the total number test per the number of weeks of analysis (eg. Phase 1 - 20 weeks)
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Acceptability of Messaging/Implementation Strategy
Description
The acceptability of each strategy will be assessed with a validated survey of the families and staff prior to the intervention and at the conclusion of the intervention being utilized.
Time Frame
1 year
Title
Feasibility of Messaging/Implementation Strategy
Description
The feasibility of each strategy will be assessed with a validated survey of the families and staff prior to the intervention and at the conclusion of the intervention being utilized.
Time Frame
1 year
Title
Appropriateness of Messaging/Implementation Strategy
Description
The appropriate of each strategy will be assessed with a validated survey of the families and staff prior to the intervention and at the conclusion of the intervention being utilized.
Time Frame
1 year
Title
Number of missed school days by students or work days by staff
Description
The total number of days missed by students and staff at the special schools during the 52 weeks of the study will be obtained.
Time Frame
52 weeks
Title
Students and staff positive SARS-CoV-2 virus
Description
The percentage of students and staff positive for SARS-CoV-2 virus will be determined
Time Frame
52 weeks
Title
School-based SARS-CoV-2 transmission events
Description
Number of possible SARS-CoV-2 transmission events occurring between students and staff within the school setting.
Time Frame
52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Students enrolled in the St. Louis Special School District or the Kennedy Krieger Institutes/Sheppard Pratt Schools in Maryland. Teachers/Staff working at the St. Louis Special Schools or the Kennedy Krieger Institutes/Sheppard Pratt Schools in Maryland dedicated to teaching children with IDD. or Parents/ of students, teachers and/or staff employed by the St. Louis Special School District or Kennedy Krieger Institute/Sheppard Pratt schools in Maryland or Families, teachers, and staff of the 67 University Centers for Excellence in Developmental Disabilities (UCEDD) which is sponsored by the Association of University Centers for Disability (AUCD). Exclusion Criteria: Members of the research team will not be eligible to participate in the focus groups.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jason G. Newland, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
Facility Name
University of Missouri
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64110
Country
United States
Facility Name
Special School District
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63131
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33098427
Citation
Lalli MA, Langmade JS, Chen X, Fronick CC, Sawyer CS, Burcea LC, Wilkinson MN, Fulton RS, Heinz M, Buchser WJ, Head RD, Mitra RD, Milbrandt J. Rapid and Extraction-Free Detection of SARS-CoV-2 from Saliva by Colorimetric Reverse-Transcription Loop-Mediated Isothermal Amplification. Clin Chem. 2021 Jan 30;67(2):415-424. doi: 10.1093/clinchem/hvaa267.
Results Reference
background
Citation
Wylie AL, Fourneir J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. medRxiv. 2020.
Results Reference
background
PubMed Identifier
32412064
Citation
Rader B, Astley CM, Sy KTL, Sewalk K, Hswen Y, Brownstein JS, Kraemer MUG. Geographic access to United States SARS-CoV-2 testing sites highlights healthcare disparities and may bias transmission estimates. J Travel Med. 2020 Nov 9;27(7):taaa076. doi: 10.1093/jtm/taaa076. No abstract available.
Results Reference
background
PubMed Identifier
32345686
Citation
Silliman Cohen RI, Bosk EA. Vulnerable Youth and the COVID-19 Pandemic. Pediatrics. 2020 Jul;146(1):e20201306. doi: 10.1542/peds.2020-1306. Epub 2020 Apr 28. No abstract available.
Results Reference
background
PubMed Identifier
32600948
Citation
Landes SD, Turk MA, Formica MK, McDonald KE, Stevens JD. COVID-19 outcomes among people with intellectual and developmental disability living in residential group homes in New York State. Disabil Health J. 2020 Oct;13(4):100969. doi: 10.1016/j.dhjo.2020.100969. Epub 2020 Jun 24.
Results Reference
background
PubMed Identifier
20235862
Citation
Ross LF, Loup A, Nelson RM, Botkin JR, Kost R, Smith GR, Gehlert S. Nine key functions for a human subjects protection program for community-engaged research: points to consider. J Empir Res Hum Res Ethics. 2010 Mar;5(1):33-47. doi: 10.1525/jer.2010.5.1.33.
Results Reference
background
PubMed Identifier
19664226
Citation
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50.
Results Reference
background
PubMed Identifier
31036028
Citation
Waltz TJ, Powell BJ, Fernandez ME, Abadie B, Damschroder LJ. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. Implement Sci. 2019 Apr 29;14(1):42. doi: 10.1186/s13012-019-0892-4.
Results Reference
background
PubMed Identifier
32690063
Citation
Zhou G, Lee MC, Atieli HE, Githure JI, Githeko AK, Kazura JW, Yan G. Adaptive interventions for optimizing malaria control: an implementation study protocol for a block-cluster randomized, sequential multiple assignment trial. Trials. 2020 Jul 20;21(1):665. doi: 10.1186/s13063-020-04573-y.
Results Reference
background
PubMed Identifier
17763914
Citation
Steiner JF. Using stories to disseminate research: the attributes of representative stories. J Gen Intern Med. 2007 Nov;22(11):1603-7. doi: 10.1007/s11606-007-0335-9. Epub 2007 Sep 1.
Results Reference
background
PubMed Identifier
28851459
Citation
Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3.
Results Reference
background
Citation
Jetter AJ, Schweinfort W. Building scenarios with Fuzzy Cognitive Mapping: An exploratory study of solar energy. Futures. 2011;43(1):52-66.
Results Reference
background
PubMed Identifier
34465306
Citation
Sherby MR, Walsh TJ, Lai AM, Neidich JA, Balls-Berry JE, Morris SM, Head R, Prener CG, Newland JG, Gurnett CA; COMPASS-T Study Group. SARS-CoV-2 screening testing in schools for children with intellectual and developmental disabilities. J Neurodev Disord. 2021 Sep 1;13(1):31. doi: 10.1186/s11689-021-09376-z.
Results Reference
derived
PubMed Identifier
34312616
Citation
Sherby MR, Walsh T, Lai AM, Neidich JA, Balls-Berry JE, Morris SM, Head R, Prener C, Newland JG, Gurnett CA; COMPASS-T Study Group. SARS-CoV-2 Screening Testing in Schools for Children with Intellectual and Developmental Disabilities. Res Sq. 2021 Jul 20:rs.3.rs-700296. doi: 10.21203/rs.3.rs-700296/v1. Preprint.
Results Reference
derived
Links:
URL
https://evaluationcenter.wustl.edu/
Description
Brown School Evaluation Center at Washington University in St. Louis
URL
http://hcrl.wustl.edu/
Description
Health Communication Research Laboratory at Washington University in St. Louis
URL
http://iddrc.wustl.edu/
Description
Intellectual and Developmental Disabilities Research Center at Washington University in St. Louis
URL
https://www.kennedykrieger.org/research/centers-labs-cores/intellectual-and-developmental-disabilities-research-center-iddrc
Description
Kennedy Krieger Institute Intellectual and Developmental Disabilities Research Center
URL
https://ihd.umkc.edu/about-ihd/
Description
UMKC Institute for Human Development

Learn more about this trial

Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic

We'll reach out to this number within 24 hrs